Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Abbvie inc. crawled date : 2021 - 05 - 24 save search
Insights on the Oncology/Cancer Drugs Global Market to 2027 - Opportunity Analysis and Industry Forecasts
Published: 2021-05-24 (Crawled : 20:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.07%
H: 0.21%
C: -0.35%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.07%
H: 0.33%
C: -0.86%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.05%
H: 0.03%
C: -1.22%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.24%
H: 0.05%
C: -0.73%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.44%
H: 0.44%
C: -1.89%
cancer drug
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Published: 2021-05-24 (Crawled : 13:15) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
disease risankizumab
The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
Published: 2021-05-24 (Crawled : 13:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.4%
H: 0.19%
C: -0.58%
results dermatitis phase 3 atopic dermatitis lancet
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.